{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:55:33Z","timestamp":1785444933635,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIABC011286-09"],"award-info":[{"award-number":["ZIABC011286-09"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT94252310625"],"award-info":[{"award-number":["HT94252310625"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217990","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:28:09Z","timestamp":1755617289000},"page":"217990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis"],"prefix":"10.1016","volume":"633","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-8487","authenticated-orcid":false,"given":"Chandrayee","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejinder Pal","family":"Khaket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanath","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangnan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden Demissie","family":"Alamaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Tabdili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriem","family":"Boufraqech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-3824","authenticated-orcid":false,"given":"Rodas","family":"Kassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electron","family":"Kebebew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canlet.2025.217990_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"American thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.canlet.2025.217990_bib2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2025.217990_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jss.2024.07.075","article-title":"Trends in mortality for anaplastic thyroid cancer: have we made progress?","volume":"302","author":"Titanji","year":"2024","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217990_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914837","article-title":"Tumor cell resistance to the inhibition of BRAF and MEK1\/2","volume":"24","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.canlet.2025.217990_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/jamaoncol.2024.2133","article-title":"Initial management of BRAF V600E-Variant anaplastic thyroid cancer: the FAST multidisciplinary group consensus statement","volume":"10","author":"Hamidi","year":"2024","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217990_bib7","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1210\/jc.2011-2671","article-title":"Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing","volume":"97","author":"Zhang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.canlet.2025.217990_bib8","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1078-0432.CCR-19-1606","article-title":"A combinatorial strategy for targeting BRAF (V600E)-mutant cancers with BRAF(V600E) inhibitor (PLX4720) and tyrosine kinase inhibitor (ponatinib)","volume":"26","author":"Ghosh","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.217990_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060965","article-title":"Using a quantitative high-throughput screening platform to identify molecular targets and compounds as repurposing candidates for endometriosis","volume":"13","author":"Churchill","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.canlet.2025.217990_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: an effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.canlet.2025.217990_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104390","article-title":"Therapeutic innovation in drug repurposing: challenges and opportunities","volume":"30","author":"Recino","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.canlet.2025.217990_bib12","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.canlet.2025.217990_bib13","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","article-title":"Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases","volume":"23","author":"Kotian","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2025.217990_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/thy.2023.0201","article-title":"Combination BRAF(V600E) inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAF(V600E)-Mutant anaplastic thyroid cancer","volume":"33","author":"Gunda","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2025.217990_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111176","article-title":"Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo","volume":"400","author":"Yang","year":"2024","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.canlet.2025.217990_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5483\/BMBRep.2025-0037","article-title":"Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal","volume":"58","author":"Ko","year":"2025","journal-title":"BMB Rep."},{"issue":"13","key":"10.1016\/j.canlet.2025.217990_bib17","doi-asserted-by":"crossref","first-page":"16517","DOI":"10.18632\/oncotarget.7760","article-title":"Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.canlet.2025.217990_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161486","article-title":"A high-throughput screen identifies 2,9-Diazaspiro[5.5]Undecanes as inducers of the endoplasmic reticulum stress response with cytotoxic activity in 3D glioma cell models","volume":"11","author":"Martinez","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.canlet.2025.217990_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217990_bib20","first-page":"615","article-title":"Synergistic effect of Dactolisib\/Lys05 combination on autophagy in A549 cells","volume":"70","author":"Abdelwahab","year":"2023","journal-title":"Acta Biochim. Pol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217990_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.slasd.2023.04.004","article-title":"High-throughput approaches to uncover synergistic drug combinations in leukemia","volume":"28","author":"Chory","year":"2023","journal-title":"SLAS Discov"},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.radmeas.2010.08.003","article-title":"Comparison of the colony formation and crystal violet cell proliferation assays to determine cellular radiosensitivity in a repair-deficient MCF10A cell line","volume":"46","author":"Veerle Vandersickel","year":"2010","journal-title":"Radiat. Meas."},{"issue":"9","key":"10.1016\/j.canlet.2025.217990_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.5713\/ajas.18.0468","article-title":"- editorial - guidelines for experimental design and statistical analyses in animal studies submitted for publication in the asian-australasian journal of animal sciences","volume":"31","author":"Seo","year":"2018","journal-title":"Asian-Australas. J. Anim. Sci."},{"issue":"5","key":"10.1016\/j.canlet.2025.217990_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5414\/CPP40221","article-title":"Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d","volume":"40","author":"Stockis","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-16","article-title":"Phase I clinical trial results of auranofin, a novel antiparasitic agent","volume":"61","author":"Capparelli","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.canlet.2025.217990_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2463","article-title":"An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2","volume":"111","author":"Walker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13046-024-03009-8","article-title":"Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217990_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13506120308998997","article-title":"Heme-oxygenase-1 response, a marker of oxidative stress, in a mouse model of AA amyloidosis","volume":"10","author":"Kamalvand","year":"2003","journal-title":"Amyloid"},{"issue":"9","key":"10.1016\/j.canlet.2025.217990_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092401","article-title":"The role of HO-1 and its crosstalk with oxidative stress in cancer cell survival","volume":"10","author":"Chiang","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.canlet.2025.217990_bib30","doi-asserted-by":"crossref","first-page":"9709","DOI":"10.1002\/cam4.5679","article-title":"Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma","volume":"12","author":"Abe","year":"2023","journal-title":"Cancer Med."},{"issue":"19","key":"10.1016\/j.canlet.2025.217990_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910519","article-title":"ROS\/TNF-alpha crosstalk triggers the expression of IL-8 and MCP-1 in human monocytic THP-1 cells via the NF-kappaB and ERK1\/2 mediated signaling","volume":"22","author":"Akhter","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.217990_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trim.2016.02.003","article-title":"Induction of IL-8(CXCL8) and MCP-1(CCL2) with oxidative stress and its inhibition with N-acetyl cysteine (NAC) in cell culture model using HK-2 cell","volume":"35","author":"Kumar","year":"2016","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.canlet.2025.217990_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114588","article-title":"Nitazoxanide impairs mitophagy flux through ROS-Mediated mitophagy initiation and lysosomal dysfunction in bladder cancer","volume":"190","author":"Sun","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217990_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122131","article-title":"Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells","volume":"332","author":"Zhang","year":"2023","journal-title":"Life Sci."},{"issue":"16","key":"10.1016\/j.canlet.2025.217990_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27165207","article-title":"Anti-cancer effects of auranofin in human lung cancer cells by increasing intracellular ROS levels and depleting GSH levels","volume":"27","author":"Cui","year":"2022","journal-title":"Molecules"},{"issue":"16","key":"10.1016\/j.canlet.2025.217990_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28165979","article-title":"Malondialdehyde as a potential oxidative stress marker for allergy-oriented diseases: an update","volume":"28","author":"Cordiano","year":"2023","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.canlet.2025.217990_bib37","article-title":"Estimation of serum malondialdehyde (A marker of oxidative stress) as a predictive biomarker for the severity of coronary artery disease (CAD) and cardiovascular outcomes","volume":"16","author":"Asfandiyar","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.canlet.2025.217990_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.exphem.2014.10.004","article-title":"Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach","volume":"43","author":"Kiebala","year":"2015","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The Gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2025.217990_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.redox.2014.12.001","article-title":"Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer","volume":"4","author":"Li","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2025.217990_bib41","series-title":"Handbook of Oxidative Stress in Cancer: Mechanistic Aspects","first-page":"1","article-title":"Thioredoxin and glutathione systems","author":"Yu","year":"2021"},{"issue":"12","key":"10.1016\/j.canlet.2025.217990_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9121257","article-title":"Thioredoxin and glutaredoxin systems as potential targets for the development of new treatments in friedreich's ataxia","volume":"9","author":"Seco-Cervera","year":"2020","journal-title":"Antioxidants"},{"issue":"10","key":"10.1016\/j.canlet.2025.217990_bib43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/ars.2015.6378","article-title":"TrxR1 as a potent regulator of the Nrf2-Keap1 response system","volume":"23","author":"Cebula","year":"2015","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.canlet.2025.217990_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101949","article-title":"Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer","volume":"42","author":"Freire Boullosa","year":"2021","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217990_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100785","article-title":"Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma","volume":"13","author":"Lippmann","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.217990_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111004","article-title":"Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer","volume":"395","author":"Hsieh","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.canlet.2025.217990_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114913","article-title":"Nitazoxanide and related thiazolides induce cell death in cancer cells by targeting the 20S proteasome with novel binding modes","volume":"197","author":"Lu","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217990_bib48","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41419-018-1058-z","article-title":"Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.canlet.2025.217990_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002691","article-title":"Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis","volume":"8","author":"Lam","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2025.217990_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellsig.2018.02.017","article-title":"Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells","volume":"46","author":"Khaket","year":"2018","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ki.2012.390","article-title":"The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease","volume":"84","author":"Cybulsky","year":"2013","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.canlet.2025.217990_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107335","article-title":"Hhatl ameliorates endoplasmic reticulum stress through autophagy by associating with LC3","volume":"300","author":"Shi","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2025.217990_bib53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14787210.2.1.43","article-title":"Nitazoxanide: a new broad spectrum antiparasitic agent","volume":"2","author":"White","year":"2004","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"2\u20133","key":"10.1016\/j.canlet.2025.217990_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12672-015-0219-0","article-title":"Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models","volume":"6","author":"Morrison","year":"2015","journal-title":"Horm Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217990_bib55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217990_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11050971","article-title":"Auranofin and pharmacologic ascorbate as radiomodulators in the treatment of pancreatic cancer","volume":"11","author":"Steers","year":"2022","journal-title":"Antioxidants"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2025.218159","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000}},{"DOI":"10.1016\/j.canlet.2025.218159","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:04:41Z","timestamp":1772831081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"alternative-id":["S0304383525005609"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217990","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217990"}}